Vivesto is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs for significant diseases, including cancer.

Pharmaceutical

Vivesto

Fredrik Järrsten is the current Chief Financial Officer at [Vivesto](/org/vivesto), a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Prior to their current position, Järrsten served as [Vivesto](/org/vivesto)'s Chief Financial Officer from March 2021 to June 2022. 

Järrsten has extensive experience in finance and accounting, having served in various leadership roles at companies such as Ernst & Young and PricewaterhouseCoopers. Fredrik holds a degree in Business Administration and Economics from the [Stockholm School of Economics](/org/stockholm-school-of-economics).

Fredrik Järrsten studied civilekonomi, with a focus on accounting and finance, at the [Stockholm School of Economics](/org/stockholm-school-of-economics). Fredrik then went on to earn their master's degree in international business from the University of Michigan - Stephen M. Ross School of Business.

They are on a team with Peter Selin - Chief Business Officer, Heidi B. Ramstad - Chief Medical Officer, and Kai Wilkinson - CTO. Fredrik Järrsten reports to Francois R. Martelet, CEO.

Fredrik Järrsten

Andrea Buscaglia is the current Director at [Vivesto](/org/vivesto). Prior to their current position, they served as the Chief Financial Officer at Endosense from November 2009 to October 2012. While at Endosense, they were responsible for a number of tasks, including the preparation of annual reports, budgeting and financial planning, investor relations, and preparing the company for a possible exit. In August 2013, Endosense was acquired by St. Jude Medical for a cash consideration of CHF 309m. In April 2016, St. Jude Medical was in turn acquired by medtech group Abbott Laboratories for a total equity value of USD 25bn.

Andrea Buscaglia received their Bachelor's Degree in Business Administration from Università Bocconi. Andrea also holds a certification from the Securities and Futures Authority ("SFA") of the United Kingdom and a certification from the University of Genova in Dottore Commercialista (Italy).

Andrea Buscaglia

Francois Martelet is an experienced Pharmaceutical and Biotechnology executive with a proven track record of shaping companies and turning around underperforming units. He has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive corporate roles at senior level at Roche, [Eli Lilly](/org/eli-lilly), [Novartis](/org/novartis) and MSD. Throughout his various assignments he has been based in six countries in Europe (including Sweden) and in the US. Francois is a Medical Doctor, with a Masters Degree in Business from France. He is also a military reserve officer holding the rank of Brigadier (OF-6) and has received the Legion of Honor on military grounds that is the highest decoration in France. 



Francois R. Martelet

Heidi B. Ramstad was appointed as Chief Medical Officer in January of 2021. Heidi B. Ramstad has more than 20 years’ experience as a medical doctor and biopharmaceutical executive in the healthcare sector. Recent positions include working for Nisonic AS as Chief Medical Officer and as Managing Director at NorMed Consulting. Dr. Ramstad has also worked for a number of blue-chip pharmaceutical companies including Roche and GSK, serving as Country Medical Director for Norway, and [Pfizer](/org/pfizer), serving as Nordic Medical Affairs Manager.



Heidi B. Ramstad

Birgit Stattin Norinder has extensive experience from international pharmaceutical and biotechnology companies in Sweden, USA and United Kingdom. Amongst many positions she has served as CEO and Chairman of Profilix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit has also held several board and chairman positions of European biotechnology companies.



Birgit Stattin Norinder

Kai Wilkinson is the current Chief Technical Officer at [Vivesto](/org/vivesto). Kai was previously a Formulation Scientist & CMC lead at [Fresenius Kabi](/org/fresenius-kabi) from August 2013 to January 2021. In this role, they were responsible for the scientific formulation of new pharmaceutical products for total parenteral nutrition and associated additives. This involved project coordination and management. Prior to that, Kai Wilkinson was a PhD-student at Swedish University of Agricultural Sciences from April 2008 to April 2013.

Kai Wilkinson has a Master's Degree in Chemical Engineering and Biotechnology from Mälardalen University. Kai also went to Rinmangymnasiet.

Some of their coworkers include Fredrik Järrsten - CFO, Peter Selin - Chief Business Officer, and Heidi B. Ramstad - Chief Medical Officer. Kai Wilkinson reports to Francois R. Martelet, CEO.

Kai Wilkinson

Visionary and strategic technology leader with repeated success leading enterprise IT operations, developing architecture, and optimizing data analysis. Extensive experience directing cross-functional teams in the design and integration of leading-edge technology solutions. Expert at launching technology programs that safeguard data, streamline operations, drive innovation, and advance business strategy. Seasoned team builder focused on acquiring and developing high-performing leaders and fostering cultures of excellence.

Rasmus Hanberg

Peter Zonabend was the CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren. Board assignments within Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB.



Peter Zonabend

Hege worked at the biotechnology company Sobi from 2013 until 2018 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within [Sanofi](/org/sanofi), VP Renal Europe and Head of Regional Liaisons at [Sanofi](/org/sanofi), VP Renal and Endocrine Europe at Genzyme and General Manager Benelux at Genzyme. Before Genzyme, she was 13 years at Baxter.



Hege Hellström

Peter has twenty years of experience within the Pharmaceutical and Biotech industry with extensive expertise within international business development. Peter has a solid track record of licensing and acquisition deals as well as successful alliance management. Prior to joining Oasmia, he has held senior positions at Inceptua and Sobi. Peter has a Bachelor Degree in Business Administration from Uppsala university, Sweden.



Peter Selin

Anders Härfstrand was the Director of Karolinska Development AB from 2017 to 2019 and as Chief Executive Officer of BBB Therapeutics BV from 2014 to 2015. Prior to that, he was President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd. (now ADAMA); President and Chief Executive Officer of Humabs BioMed SA; and Chief Executive Officer of Nitec Pharma AG (now Horizon Pharmaceuticals). He has also served in various executive roles at Serono, [Pfizer](/org/pfizer) and Pharmacia. He has a significant operational global experience of the pharmaceutical industry especially from the US, Japan and Europe.



Vivesto

Org chart

Teams

Board of Directors

CEO and Executive Team

Leadership Team

Discover similar companies